Mcclain Robert L, Ramakrishna Harish, Aniskevich Stephen, Cartwright Joseph A, Phar Leah G Ward, Pai Sher-Lu, Rodrigues Eduardo S, Martin Archer K, Shine Timothy S
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Curr Clin Pharmacol. 2015;10(1):35-46. doi: 10.2174/1574884709666140212110036.
The number of patients with end stage liver disease is growing worldwide. This is likely a result of advances in medical science that have allowed these patients to lead longer lives since the incidence of diseases such as alcoholic cirrhosis and viral hepatitis have remained stable or even decreased in recent years, at least in more developed nations. Many of these patients will require anesthetic care at some point. The understanding and application of basic principles of pharmacokinetics is paramount to the practice of anesthesia. An understanding of pharmacokinetic principles provides the anesthesiologist with a scientific foundation for achieving therapeutic objectives associated with the use of any drug; however, pathologic conditions often alter the expected kinetic profile of many drugs. Anesthesia providers caring for these patients must be aware of the altered pharmacokinetics that may occur in these patients. We review normal liver physiology, pathophysiology of liver disease in general, and how liver failure affects the pharmacokinetics and pharmacodynamics of anesthetic agents; providing some specific examples.
全球范围内,终末期肝病患者的数量正在增加。这可能是医学科学进步的结果,这些进步使这些患者能够活得更长,因为近年来酒精性肝硬化和病毒性肝炎等疾病的发病率保持稳定甚至有所下降,至少在较发达国家是这样。这些患者中的许多人在某个时候都需要麻醉护理。药代动力学基本原理的理解和应用对于麻醉实践至关重要。对药代动力学原理的理解为麻醉医生实现与使用任何药物相关的治疗目标提供了科学基础;然而,病理状况常常会改变许多药物的预期动力学特征。照顾这些患者的麻醉医护人员必须意识到这些患者可能出现的药代动力学改变。我们回顾正常肝脏生理学、一般肝病的病理生理学,以及肝衰竭如何影响麻醉药物的药代动力学和药效学;并提供一些具体实例。